Daniel Hubschmann
Overview
Explore the profile of Daniel Hubschmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glaser S, Fischer A, Martinez-Manjon J, Lopez C, Kretzmer H, Burkhardt B, et al.
Leukemia
. 2025 Mar;
PMID: 40065077
No abstract available.
2.
Rieke D, Bitzer M, Bleckmann A, Desuki A, Ernst T, Esposito I, et al.
Eur J Cancer
. 2025 Mar;
220:115331.
PMID: 40058270
Precision oncology is a multi-step process including patient selection, tumor profiling, molecular tumor board discussion and personalized cancer management. So far, it remains largely unstandardized. The implementation of precision oncology...
3.
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
Tremmel R, Hubschmann D, Schaeffeler E, Pirmann S, Frohling S, Schwab M
Pharmacol Rev
. 2025 Feb;
77(1):100014.
PMID: 39952686
Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or are in development. Personalized pharmacotherapy in oncology has so far been based...
4.
Lutz R, Poos A, Sole-Boldo L, John L, Wagner J, Prokoph N, et al.
Sci Immunol
. 2025 Feb;
10(104):eadp6667.
PMID: 39919199
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However,...
5.
Kerle I, Gross T, Kogler A, Arnold J, Werner M, Eckardt J, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):9.
PMID: 39794422
Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) and transcriptome sequencing (TS) with broad panel sequencing...
6.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
7.
Lutz R, Grunschlager F, Simon M, Awwad M, Bauer M, Yousefian S, et al.
Nat Commun
. 2024 Nov;
15(1):10396.
PMID: 39613747
The long-term consequences of cancer and its therapy on the patients' immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow...
8.
Kobbe G, Bruggemann M, Baermann B, Wiegand L, Trautmann H, Yousefian S, et al.
N Engl J Med
. 2024 Nov;
391(13):1217-1226.
PMID: 39589371
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary...
9.
Rheinnecker M, Frohlich M, Rubsam M, Paramasivam N, Heilig C, Frohling S, et al.
Bioinform Adv
. 2024 Apr;
4(1):vbae017.
PMID: 38560552
Summary: ZygosityPredictor provides functionality to evaluate how many copies of a gene are affected by mutations in next generation sequencing data. In cancer samples, the tool processes both somatic and...
10.
Bundschuh C, Weidner N, Klein J, Rausch T, Azevedo N, Telzerow A, et al.
Infect Genet Evol
. 2024 Feb;
119:105577.
PMID: 38403035
In January 2021, the monitoring of circulating variants of SARS-CoV-2 was initiated in Germany under the Corona Surveillance Act, which was discontinued after July 2023. This initiative aimed to enhance...